Evidence map›Paper›PMID 29869106›Full record

ArticleAdvances in therapy2018

Dosing Patterns and Economic Burden of Palbociclib Drug Wastage in HR+/HER2- Metastatic Breast Cancer.

Anand A Dalal, Patrick Gagnon-Sanschagrin, Rebecca Burne, Annie Guérin, Geneviève Gauthier, Tania Small, Polly Niravath

Abstract read
PubMed Publisher
In one paragraph

Article in Advances in therapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Optimising oncology drug expenditure in Ireland.Irish journal of medical science · 2024
    Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Anand A DalalNovartis Pharmaceuticals Corporation, East Hanover, NJ, 07936, USA.
Patrick Gagnon-SanschagrinAnalysis Group, Inc., Montreal, QC, H3B4W5, Canada.
Rebecca BurneAnalysis Group, Inc., Montreal, QC, H3B4W5, Canada.
Annie GuérinAnalysis Group, Inc., Montreal, QC, H3B4W5, Canada.
Geneviève GauthierAnalysis Group, Inc., Montreal, QC, H3B4W5, Canada. medicalwriting@analysisgroup.com.
Tania SmallNovartis Pharmaceuticals Corporation, East Hanover, NJ, 07936, USA.
Polly NiravathHouston Methodist Hospital, Houston, TX, 77030, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionTargeted therapies have revolutionized the treatment of hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2-) metastatic breast cancer (mBC). However, as for many oncology drugs, the dose of targeted therapies may need to be adjusted over time, leading to drug wastage when a dose modification is needed but the dose cannot be split or saved. This has been shown to be the case for palbociclib and has led to concerns among payers. This study described palbociclib dosing patterns and estimated the economic burden of the drug wastage associated with palbociclib dose modifications in postmenopausal women with HR+/HER2- mBC.

methodsA large US claims database was used to identify postmenopausal women with HR+/HER2- mBC who received a palbociclib-based therapy during one of their first three lines of therapy for mBC between February 2015 (palbociclib approval) and December 2015. Dosing patterns (dosing modifications and sequences) were reported; a dose modification was defined as an increase/decrease of at least 25 mg daily compared to the preceding dose. Estimates of drug wastage costs were based on days with overlap in prescription fills for different palbociclib doses.

resultsA total of 473 postmenopausal palbociclib-treated women with HR+/HER2- mBC were included (first line 214; second line 157; third line 120). Over an average duration of line of therapy of approximately 4 months, dose modification was observed in 17.8%, 31.2%, and 35.0% of patients in first, second, and third line. Average overlap in prescription fills was 9.2, 9.9, and 5.4 days in first, second, and third line. This potential drug wastage resulted in an average cost of $4376, $4740, and $2592 per patient in first, second, and third line.

conclusionsThis study showed that drug wastage due to palbociclib dose modification results in substantial costs. Treatment options with more flexible dosing may help reduce the costs of drug wastage.

fundingNovartis Pharmaceuticals Corporation.

Indexed as

Cost of IllnessAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsDose-Response Relationship, DrugDrug CostsFemaleHumansMiddle AgedPiperazinesPyridinesUnited StatespalbociclibPiperazinesPyridinesDose modificationDrug wastageEconomic burdenHR+/HER2− metastatic breast cancerOncologyPalbociclib

Identifiers

PMID29869106

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.